Search

Your search keyword '"Huang, Chi-Jung"' showing total 244 results
Start Over Author "Huang, Chi-Jung" Search Limiters Full Text
244 results on '"Huang, Chi-Jung"'

1. Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure

Author

Chang, Wei‐Lun, primary, Chen, Ying‐Fan, additional, Lee, Yu‐Hsuan, additional, Shiu, Ming‐Neng, additional, Chang, Po‐Yin, additional, Guo, Chao‐Yu, additional, Huang, Chi‐Jung, additional, Chiang, Chern‐En, additional, Chen, Chen‐Huan, additional, Chuang, Shao‐Yuan, additional, and Cheng, Hao‐Min, additional

Published
2024
Full Text
View/download PDF

20. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing

Author

Huang, Chi-Cheng, primary, Liu, Chih-Yi, additional, Huang, Chi-Jung, additional, Hsu, Yao-Chun, additional, Lien, Heng-Hui, additional, Wong, Jia-Uei, additional, Tai, Feng-Chuan, additional, Ku, Wen-Hui, additional, Hung, Chi-Feng, additional, Lin, Jaw-Town, additional, Huang, Ching-Shui, additional, and Chiang, Han-Sun, additional

Published
2022
Full Text
View/download PDF

28. Correction: Weng et al. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. Cancers 2020, 12, 3426

Author

Weng, Ching-Fu, primary, Huang, Chi-Jung, additional, Huang, Shih-Hung, additional, Wu, Mei-Hsuan, additional, Tseng, Ailun Heather, additional, Sung, Yung-Chuan, additional, Lee, Henry Hsin-Chung, additional, and Ling, Thai-Yen, additional

Published
2021
Full Text
View/download PDF

30. Additional file 1 of The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials

Author

Sung, Shih-Hsien, Yeh, Wan-Yu, Chiang, Chern-En, Huang, Chi-Jung, Huang, Wei-Ming, Chen, Chen-Huan, and Cheng, Hao-Min

Abstract

Additional file 1: Supplemental Table S1. The PRISMA 2020 checklist. Supplemental Table S2. Characteristics of the randomized controlled trials identified for the study (2-1). Supplemental Table S3. Characteristics of the randomized controlled trials identified for the study (2-2). Supplemental Table S4. GRADE Evidence Profile of Certainity assessment and Importance. Supplemental Figure S1. Risk of bias summary of 21 studies according to the Cochrane Handbook for Systematic Reviews of Interventions (���+���: low risk; ���-���: high risk; ���?���: unclear risk).

Published
2021
Full Text
View/download PDF

33. A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer

Author

Chang, Shih-Chang, Shen, Ming-Hung, Liu, Chih-Yi, Pu, Chi-Ming, Hu, Je-Ming, and Huang, Chi-Jung

Subjects
1,2-dimethylhydrazine, colorectal cancer, Articles, butyrate, Butyricicoccus pullicaecorum, digestive system diseases
Abstract

Gut microbes influence tumor development and progression in the intestines and may provide a novel paradigm for the treatment of colorectal cancer (CRC). Gut dysbiosis may be associated with the development and progression of CRC. Identifying the interactions between the colonic tract and gut microbiota may provide novel information relevant to CRC prevention. The present study examined the effects of butyrate-producing Butyricicoccus pullicaecorum (B. pullicaecorum) on mice with 1,2-dimethylhydrazine (DMH)-induced CRC and the microbial metabolite of B. pullicaecorum on CRC cells. Immunohistochemical staining of the mouse colon tissues and reverse transcription PCR of CRC cells were used to determine the protein and mRNA expression levels of the short-chain fatty acid (SCFA) transporter solute carrier family 5 member 8 (SLC5A8) and G-protein-coupled receptor 43 (GPR43). In CRC-bearing mice fed B. pullicaecorum, DMH-induced CRC regressed, body weight increased and serum carcinoembryonic antigen levels decreased. Notably, SLC5A8 and GPR43 were diffusely and moderately to strongly expressed in the neoplastic epithelial cells and underlying muscularis propria in the colons of the mice. In conclusion, administration of B. pullicaecorum or its metabolites improved the clinical outcome of CRC by activating the SCFA transporter and/or receptor. These results indicated that B. pullicaecorum was a probiotic with anti-CRC potential.

Published
2020

36. Feasibility and rationale of direct current cardioversion immediately after transcatheter percutaneous edge-to-edge mitral valve repair

Author

Lee, Ching-Wei, Frerker, Christian, Huang, Wei-Ming, Tsai, Yi-Lin, Huang, Chi-Jung, Yu, Wen-Chung, Hsu, Chiao-Po, Chiang, Chern-En, Chen, Chen-Huan, Sung, Shih-Hsien, Lee, Ching-Wei, Frerker, Christian, Huang, Wei-Ming, Tsai, Yi-Lin, Huang, Chi-Jung, Yu, Wen-Chung, Hsu, Chiao-Po, Chiang, Chern-En, Chen, Chen-Huan, and Sung, Shih-Hsien

Abstract

Aims Atrial fibrillation (AF) is a frequent comorbidity among patients with severe mitral regurgitation (MR). Direct current (DC) cardioversion is one of the strategies for rhythm control. However, the safety and feasibility of immediate DC cardioversion after MitraClip are not elucidated. Methods and Results In this study, patients with symptomatic severe MR who underwent MitraClip were included. After fixing the MR, synchronized DC cardioversion was attempted for those with AF. A total of consecutive 60 patients, 36 subjects (60%), comorbid with AF. DC cardioversion was performed in 30 patients (mean age of 76.0 +/- 9.3 years), and the successful conversion was achieved in 15 patients (50%). There was no any adverse event related to the cardioversion. Subjects with sustained conversion to SR experienced significant improvement in 6MWT (failed: 285 +/- 110-308 +/- 135 m,P = .278; successful: 269 +/- 109 m-328 +/- 78,P = .047) and reduction in NT-proBNP level (failed: 4411 +/- 7401-3296 +/- 4299 ng/mL,P = .217; successful: 4094 +/- 2735-2353 +/- 2856 ng/mL,P = .026) at 1 month. Conclusions Direct current cardioversion seemed to be safe and feasible immediately after the transcatheter edge-to-edge mitral valve repairs. Subjects who maintain SR experienced better functional improvement.

Published
2020

47. Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma

Author

Ho Chih-Ming, Huang Chi-Jung, Huang Chia-Yen, Wu Yih-Yiing, Chang Shwu-Fen, and Cheng Wen-Fang

Subjects
Ovarian clear cell adenocarcinoma, Methylation-specific multiplex ligation-dependent probe amplification, HIN-1, CACNA1A, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background This study is to analyze promoter methylation of various tumor suppressor genes in different types of ovarian carcinoma and to identify potential therapeutic targets of ovarian clear cell adenocarcinoma (OCCA). Materials and methods The promoter methylation statuses of 40 genes in primary ovarian carcinomas including 47 clear- and 63 non-clear-cell type tissues, 6 OCCA cell lines, 29 benign ovarian endometriotic cysts, and 31 normal controls were analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). The MS-MLPA results were correlated with clinicopathological features and outcomes of 47 OCCA patients. Functions of the target genes were further explored by Western Blot Analysis, apoptosis assay, and caspase-3/7 activity analysis. Results Frequencies of methylated RASSF1A, CDH13, CACNA1A, HIN-1, and sFRP5 genes in OCCA tissues were significantly higher than those in non-OCCA cancerous tissues and benign endometriotic cysts. The expected OS for patients with methylated promoters of HIN-1 was significantly worse than those for patients without methylated HIN-1 (30% vs. 62%, p = 0.002). The HIN-1 gene was over-expressed in ES2 cells, a significant reduction in cell growth and induction of apoptosis, and increasing paclitaxel sensitivity by reducing phosphorylation of Akt were observed. Conclusions Methylation of HIN-1 promoter is a novel epigenetic biomarker associated with poor outcomes in OCCA patients. Ectopic expression of the HIN-1 gene increased paclitaxel sensitivity which is partly through Akt pathway.

Published
2012
Full Text
View/download PDF

50. A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

Author

Chen Yan-Chu, Chien Chih-Cheng, Lin Chih-Ming, Yang Shung-Haur, Huang Shih-Ming, Huang Chi-Jung, Lee Chia-Long, Wu Hao-Han, and Chang Chun-Chao

Subjects
Medicine
Abstract

Abstract Background Colorectal cancer (CRC) is the predominant gastrointestinal malignancy and the leading cause of cancer death. The identification of genes related to CRC is important for the development of successful therapies and earlier diagnosis. Methods Molecular analysis of feces was evaluated as a potential method for CRC detection. Expression of a predicted protein with unknown function, KIAA0247, was found in feces evaluated using specific quantitative real-time polymerase chain reaction. Its cellular function was then analyzed using immunofluorescent staining and the changes in the cell cycle in response to 5-fluorouracil (5-FU) were assessed. Results Gastrointestinal tissues and peripheral blood lymphocytes ubiquitously expressed KIAA0247. 56 CRC patients fell into two group categories according to fecal KIAA0247 mRNA expression levels. The group with higher fecal KIAA0247 (n = 22; ≥ 0.4897) had a significantly greater five-year overall survival rate than the group with lower fecal KIAA0247 (n = 30; < 0.4897) (66.0 ± 11.6%; p = 0.035, log-rank test). Fecal expression of KIAA0247 inversely related to CRC tumor size (Kendall's tau-b = -0.202; p = 0.047). Immunofluorescent staining revealed that the cytoplasm of CRC cells evenly expresses KIAA0247 without 5-FU treatment, and KIAA0247 accumulates in the nucleus after 40 μM 5-FU treatment. In HCT116 p53-/- cells, which lack p53 cell cycle control, the proportion of cells in the G2/M phase was larger (13%) in KIAA0247-silent cells than in the respective shLuc control (10%) and KIAA0247-overexpressing cells (7%) after the addition of low dose (40 μM) 5-FU. Expression of three cyclin genes (cyclin A2, cyclin B1, and cyclin B2) also downregulated in the cells overexpressing KIAA0247. Conclusions This is the first description of a linkage between KIAA0247 and CRC. The study's data demonstrate overexpression of KIAA0247 associates with 5-FU therapeutic benefits, and also identify the clinical significance of fecal KIAA0247 in CRC.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results